Capstone Therapeutics Corporation has entered into a significant stock purchase agreement with an accredited investor, involving the potential sale of up to $20 million in common stock. Under the terms of this agreement, Capstone has the option to sell shares to the investor, priced at 97% of the lowest daily volume-weighted average price over a three-day period. Additionally, a recent amendment to this agreement has increased the limits on the volume and dollar amount of shares that can be purchased in a single transaction. This amendment allows for a maximum purchase of up to 40% of the trading volume or $3 million, whichever is lower, enhancing Capstone's financial flexibility and capital-raising options.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。